Robert Moses offers a critical response to Robert A. Caro's biography, disputing the portrayal of his public service, addressing inaccuracies, and defending his contributions to urban development in New York.
On the Impossible: Why Cassava Sciences’ simufilam will fail Phase 3 clinical trials and the stock will trade to $2
The text analyzes Cassava Sciences' simufilam, predicting its failure in Phase 3 trials for Alzheimer's disease due to ineffective mechanisms, poor pharmacokinetics, and manipulative data practices.